Suppliers and packagers for CETROTIDE

CETROTIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Emd Serono Inc	CETROTIDE	cetrorelix acetate	POWDER;SUBCUTANEOUS	021197	NDA	EMD Serono, Inc.	44087-1225-1	1 KIT in 1 CARTON (44087-1225-1) * 1 mL in 1 VIAL, GLASS * 1 mL in 1 SYRINGE, GLASS	2000-08-11

Last updated: July 30, 2025

ppliers for the Pharmaceutical Drug: CETROTIDE

Introduction
CETROTIDE (cetrorelix acetate) is a gonadotropin-releasing hormone (GnRH) antagonist primarily used in assisted reproductive technology (ART) procedures, notably in ovarian stimulation protocols to prevent premature luteinizing hormone (LH) surges. Its efficacy, safety profile, and market dominance depend significantly on the availability of reliable suppliers. This article explores the key manufacturers, distribution channels, and emerging suppliers for CETROTIDE, providing critical insights for stakeholders across the pharmaceutical supply chain.

Overview of CETROTIDE and Its Market Significance
CETROTIDE serves a vital role in fertility treatments, contributing to successful in-vitro fertilization (IVF) outcomes. The drug's global demand is linked to the rising prevalence of infertility, increasing use of ART, and advancements in reproductive healthcare. The patent lifecycle, regulatory approvals, and manufacturing capabilities influence current supplier options, with major pharmaceutical companies leading the supply chain.

Major Suppliers and Manufacturers of CETROTIDE

1. Ferring Pharmaceuticals

Ferring Pharmaceuticals, a Swiss-based biopharmaceutical company, is the primary developer and proprietary manufacturer of CETROTIDE. Since its market introduction, Ferring has maintained exclusive rights to the drug, leveraging its extensive global distribution network. The company's commitment to reproductive health and fertility treatments positions it as the dominant supplier.

Manufacturing and Supply Capabilities
Ferring operates multiple manufacturing plants within Europe and Asia, ensuring a stable supply chain. Its facilities integrate quality assurance protocols aligned with international standards (e.g., EMA, FDA), supporting GMP compliance. Ferring's robust R&D pipeline continually enhances CETROTIDE's formulation and delivery options.

2. Generic Manufacturers and Market Entrants

Following the expiration of patent rights or regulatory approvals in certain jurisdictions, multiple generic manufacturers have entered the CETROTIDE market. These include companies based in India, China, and Eastern Europe, offering cost-effective alternatives to Ferring’s branded product.

Notable Generic Suppliers

• Sun Pharma (India)
• Cipla (India)
• Galaxy Surfactants (India)
• Zhuhai Liantang Pharmaceutical (China)
  These companies manufacture CETROTIDE, often under local regulatory approvals, and supply to regional markets. However, their products may vary in terms of bioequivalence, packaging, and regulatory acceptance globally.

Regulatory and Patent Considerations
Most generic manufacturers operate in markets where patent protections for CETROTIDE have expired or are not enforceable. Differences in regulatory standards can impact the acceptance of generics in developed markets like the US, European Union, and Japan, limiting their availability in these regions.

3. Contract Manufacturing and ODMs

Some companies engage in contract manufacturing or outsource production via original development and manufacturing organizations (CDMOs). These arrangements enable advanced economies to meet local demand without direct manufacturing investments. While specific companies are confidential, this practice ensures supply flexibility.

4. Distributors and Supply Chain Intermediaries

Global medical distributors and pharmaceutical wholesalers procure CETROTIDE from primary manufacturers and supply hospitals, clinics, and fertility centers worldwide. Leading distribution networks include McKesson, Cardinal Health, and regional distributors tailored to specific markets.

Distribution Challenges

• Ensuring cold chain integrity during transit.
• Navigating regional regulatory clearance.
• Maintaining stock levels amid supply chain disruptions.

Supply Dynamics and Emerging Trends

5. Impact of Regulatory and Patent Landscape

The exclusivity period granted to Ferring limits manufacturing rights and market penetration for competitors. However, patent lapses or legal challenges have facilitated generic entries in certain countries, diversifying suppliers. Regulatory harmonization via agencies such as the EMA and FDA advances market access, but regional differences persist.

6. Supply Chain Risks and Opportunities

Supply chain disruptions, such as geopolitical tensions, manufacturing delays, or regulatory hurdles, can significantly impact CETROTIDE availability. Conversely, increased manufacturing capacity, especially in emerging markets, offers opportunities for competitive pricing and localized supply.

7. Future Market Outlook

Emerging biosimilar and generic players aim to challenge Ferring’s dominance, leveraging global demand growth. Innovative drug delivery systems, including subcutaneous formulations, may also influence supplier strategies. Investments in manufacturing capacity and regulatory approvals will shape CETROTIDE’s supply landscape for the coming decade.

Conclusion
The CETROTIDE supply landscape is characterized by Ferring's monopolistic position supported by proprietary manufacturing, complemented by a growing cadre of generic manufacturers in developing regions. The balance of power is poised to shift with patent expirations, regional regulations, and technological advancements. Stakeholders must monitor licensing developments, manufacturing capacity, and regulatory approvals to navigate this evolving environment effectively.

Key Takeaways

• Ferring Pharmaceuticals remains the principal and sole branded CETROTIDE supplier globally.
• Generic manufacturers are active primarily in emerging markets, offering cost-effective alternatives upon patent expiration.
• Supply chain stability depends on manufacturing capacities, regulatory approvals, and distribution networks.
• Regional regulatory landscapes influence the availability and acceptance of CETROTIDE across different markets.
• Future growth hinges on biosimilar entry, technological innovations, and strategic manufacturing investments.

FAQs

1. Who is the primary supplier of CETROTIDE globally?
Ferring Pharmaceuticals is the exclusive manufacturer and supplier of CETROTIDE in most markets worldwide, maintaining proprietary rights and a comprehensive distribution network.

2. Are there generic alternatives to CETROTIDE?
Yes, after patent expirations in certain regions, several generic manufacturers from India and China supply CETROTIDE at lower costs, though their availability varies by country due to regulatory and patent restrictions.

3. How does regulatory approval influence CETROTIDE suppliers?
Regulatory approvals determine market access; stringent standards may delay generic entry into developed markets, while regional approvals facilitate localized manufacturing and supply.

4. What risks threaten CETROTIDE supply continuity?
Risks include manufacturing delays, geopolitical disruptions, regulatory hurdles, and supply chain fragility, all of which can impact drug availability and pricing.

5. What does the future hold for CETROTIDE suppliers?
Market expansion driven by rising infertility rates, technological innovations in drug formulations, and biosimilar development indicate a dynamic supply landscape poised for growth and diversification.

References

1. Ferring Pharmaceuticals. CETROTIDE product information.
2. European Medicines Agency (EMA). CETROTIDE approval details.
3. U.S. Food and Drug Administration (FDA). Generic drugs and biosimilars overview.
4. Market research reports on fertility drugs and biosimilars.
5. Industry analyses on pharmaceutical manufacturing and distribution.